Theoretical quantitative evaluation of the intercalative binding to DNA of the new antitumor drug 9-amino-acridine-4-carboxamide indicates that, in contradiction with a recently proposed model, the compound should show specificity for interaction with the major (and not minor) groove of GC sequences.
